| 1. |
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355(14):1419-1431.
|
| 2. |
Kaiser PK, Brown DM, Zhang K, et al.Ranibizumab for predominantly classic neovascular age-related macular degeneration:subgroup analysis of first-year ANCHOR results[J]. Am J Ophthalmol, 2007, 144(6):850-857.
|
| 3. |
Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration:a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2008, 115(10):1837-1846.
|
| 4. |
Krebs I, Glittenberg C, Ansari-Shahrezaei S, et al. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration[J].Br J Ophthalmol, 2013, 97(11):1443-1446.
|
| 5. |
Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration[J].Ophthalmology, 2007, 114(2):246-252.
|
| 6. |
Kruger Falk M, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment[J]. Am J Ophthalmol, 2013, 155(1):89-95.
|
| 7. |
Yamashiro K, Tomita K, Tsujikawa A, et al.Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment[J].Am J Ophthalmol, 2012, 154(1):125-136.
|
| 8. |
Menghini M, Kurz-Levin MM, Amstutz C, et al. Response to ranibizumab therapy in neovascular AMD-an evaluation of good and bad responders[J]. Klin Monbl Augenheilkd, 2010, 227(4):244-248.
|
| 9. |
Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration[J]. Am J Ophthalmol, 2007, 143(3):566-583.
|
| 10. |
Tano Y, Ohji M. EXTEND-I:safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration[J]. Acta Ophthalmol, 2010, 88(3):309-316.
|
| 11. |
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355(14):1432-1444.
|
| 12. |
Suzuki M, Nagai N, Izumi-Nagai K, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration[J]. Br J Ophthalmol, 2014, 98(9):1186-1191.
|
| 13. |
叶湘湘, 陈中山, 丁琴, 等.玻璃体腔注射雷珠单抗与光动力疗法联合玻璃体腔注射雷珠单抗治疗特发性脉络膜新生血管的疗效比较[J].中华眼底病杂志, 2013, 29(4):362-366.
|
| 14. |
Krebs I, Brannath W, Glittenberg C, et al. Posterior vitreomacular adhesion:a potential risk--factor for exudative age-related macular degeneration[J]. Am J Ophthalmol, 2007, 144(5):741-746.
|
| 15. |
Krebs I, Glittenberg C, Zeiler F, et al.Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal in adhesions exudative age-related macular degeneration[J]. Br J Ophthalmol, 2011, 95(10):1415-1418.
|
| 16. |
Robison CD, Kerbs I, Binder S, et al.Vitreomacular adhesion in active and end-stage age-related macular degeneration[J]. Am J Ophthalmol, 2009, 148(1):79-82.
|
| 17. |
Schmidt JC, Mennel S, Hoerle S, et al. High incidence of vitreomacular traction in recurrent choroidal neovascularization after repeated photodynamic therapy[J]. Br J Ophthalmol, 2006, 90(11):1361-1362.
|
| 18. |
Takeda A, Baffi JZ, Kleinman ME, et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy[J]. Nature, 2009, 460(7252):225-230.
|
| 19. |
Rosenfeld PJ, Rich RM, Lalwani GA.Ranibizumab:phaseⅢclinical trial results[J]. Ophthalmol Clin North Am, 2006, 19(3):361-372.
|
| 20. |
Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration[J]. Retina, 2006, 26(8):859-870.
|
| 21. |
Peter JF. The influence of genetics on response to treatment with ranibizumab(Lucentis) for age-related macular degeneration:the Lucentis genotype study(An American ophthalmological society thesis)[J].Trans Am Ophthalmol Soc, 2011, 109:115-156.
|
| 22. |
Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD[J].Invest Ophthalmol Vis Sci, 2011, 52(7):4694-4702.
|
| 23. |
McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration[J]. Br J Ophthalmol, 2012, 96(2):208-212.
|
| 24. |
Teper SJ, Nowińska A, Pilat J, et al. Involvement of genetic factors in the response to a variable dosing ranibizumab treatment regimen for age-related macular degeneration[J]. Mol Vis, 2010, 16(7):2598-2604.
|
| 25. |
Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab[J].Br J Ophthalmol, 2009, 93(5):610-613.
|
| 26. |
Hayashi H, Yamashiro K, Gotoh N, et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation[J].Invest Ophthalmol Vis Sci, 2010, 51(11):5914-5919.
|
| 27. |
Kondo N, Bessho H, Honda S, et al. Complement factor H Y402H variant and risk of age-related macular degeneration in Asians:a systematic review and meta-analysis[J]. Ophthalmology, 2011, 118(2):339-344.
|
| 28. |
Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med, 2011, 364(20):1897-1908.
|
| 29. |
de Oliveira Dias JR, Rodrigues EB, Maia M, et al.Cytokines in neovascular age-related macular degeneration:fundamentals of targeted combination therapy[J].Br J Ophthalmol, 2011, 95(12):1631-1637.
|
| 30. |
Wang Y, Wang VM, Chan CC.The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment[J]. Eye, 2011, 25(2):127-139.
|
